GlassScriptPhysician profile
Michelle Starnes
NPI 1487052445
$6,559.16
in general payments reported to CMS, 2019-2025
46 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,824 · 2022: $1,122 · 2023: $1,464 · 2024: $850 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,528 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,527.90 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,498.49 | 2021-2025 | |
| Novo Nordisk INC | $1,102.75 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $549.97 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $442.15 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $264.64 | 2021-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $258.75 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Idorsia Pharmaceuticals US INC | $239.42 | 2022-2024 | Quviviq |
| Pfizer INC. | $197.48 | 2021-2025 | |
| Axsome Therapeutics, INC. | $181.79 | 2024-2025 | Auvelity, Symbravo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.92 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $146.04 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $137.55 | 2023-2025 | Rexulti |
| Abbott Laboratories | $118.58 | 2021-2025 | Freestyle Libre 3, Eterna |
| Bayer Healthcare Pharmaceuticals INC. | $117.93 | 2021-2025 | |
| Dexcom, INC. | $113.90 | 2023-2025 | Dexcom G6 Transmitter |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Starnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.